NCOA4-RET fusion
|
Thyroid Gland Papillary Carcinoma
|
NCOA4-RET fusion
|
Thyroid Gland Papillary Carcinoma
|
lenvatinib Sensitive: C4 – Case Studies
|
lenvatinib Sensitive: C4 – Case Studies
|
NCOA4-RET fusion
|
Thyroid Gland Carcinoma
|
NCOA4-RET fusion
|
Thyroid Gland Carcinoma
|
pralsetinib Sensitive: C4 – Case Studies
|
pralsetinib Sensitive: C4 – Case Studies
|
NCOA4-RET fusion
|
Cholangiocarcinoma
|
NCOA4-RET fusion
|
Cholangiocarcinoma
|
pralsetinib Sensitive: C4 – Case Studies
|
pralsetinib Sensitive: C4 – Case Studies
|
NCOA4-RET fusion
|
NSCLC
|
NCOA4-RET fusion
|
NSCLC
|
RXDX-105 Sensitive: D – Preclinical
|
RXDX-105 Sensitive: D – Preclinical
|